Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -116.74% is 51% above its 3-year average of -238.73%, near the high end of its 3-year range (-624.67%–-70.81%).
As of the fiscal period ended Tuesday, June 30, 2026. 27.03% above its 12-month average of -159.98%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -116.74%.
RETURN ON EQUITY (ROE)
-116.74%
RETURN ON EQUITY (ROE) AVG TTM
-159.98%
RETURN ON EQUITY (ROE) AVG 3Y
-238.73%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+27.03%
CURRENT VS 3Y AVG
+51.10%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-177.88%
vs the sector median at left
Telomir Pharmaceuticals, Inc. Common Stock
Market Cap
$82.53M
Return on Equity (ROE)
-116.74%
TTM Avg
-159.98%
3Y Avg
-238.73%
5Y Avg
N/A
Market Cap
$82.47M
Return on Equity (ROE)
-150.95%
TTM Avg
-77.89%
3Y Avg
-62.90%
5Y Avg
-47.80%
Market Cap
$82.59M
Return on Equity (ROE)
-85.48%
TTM Avg
1586.35%
3Y Avg
184842.55%
5Y Avg
123293.37%
Market Cap
$82.29M
Return on Equity (ROE)
232.78%
TTM Avg
-18.33%
3Y Avg
-28.65%
5Y Avg
-29.96%
Market Cap
$81.22M
Return on Equity (ROE)
-28.85%
TTM Avg
-24.95%
3Y Avg
-20.92%
5Y Avg
-19.20%
Market Cap
$81.20M
Return on Equity (ROE)
-130.67%
TTM Avg
-143.13%
3Y Avg
-106.90%
5Y Avg
-90.63%
Market Cap
$84.13M
Return on Equity (ROE)
-50.80%
TTM Avg
-124.86%
3Y Avg
-88.30%
5Y Avg
-60.21%
Market Cap
$80.30M
Return on Equity (ROE)
-309.44%
TTM Avg
-515.53%
3Y Avg
-464.77%
5Y Avg
-329.14%
Market Cap
$79.61M
Return on Equity (ROE)
-85.65%
TTM Avg
-57.41%
3Y Avg
-45.73%
5Y Avg
-8.61%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $82.53M | -116.74% | -159.98% | -238.73% | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.47M | -150.95% | -77.89% | -62.90% | -47.80% |
| ProMIS Neurosciences, Inc. (PMN)vs › | $82.59M | -85.48% | 1586.35% | 184842.55% | 123293.37% |
| LENSAR Inc (LNSR)vs › | $82.29M | 232.78% | -18.33% | -28.65% | -29.96% |
| MediciNova, Inc. (MNOV)vs › | $81.22M | -28.85% | -24.95% | -20.92% | -19.20% |
| Nutriband Inc. (NTRB)vs › | $81.20M | -130.67% | -143.13% | -106.90% | -90.63% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | -50.80% | -124.86% | -88.30% | -60.21% |
| Humacyte, Inc. (HUMA)vs › | $80.30M | -309.44% | -515.53% | -464.77% | -329.14% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | -85.65% | -57.41% | -45.73% | -8.61% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $85.86M | -105.20% | -53.79% | -41.98% | -32.71% |
ROE
-116.7%
ROA
-109.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -116.74% |
| 2026-03-31 | -185.89% |
| 2025-12-31 | -176.10% |
| 2025-09-30 | -161.20% |
| 2024-03-31 | -624.67% |
| 2023-12-31 | -380.19% |
| 2023-09-30 | -194.29% |
| 2023-06-30 | -70.81% |
